Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China

Qian Xu; Chunli Wang; Wei Cheng; Yingzi Zhen; Yaguang Ding; Guoqing Liu; Wanru Yao; Zhenping Chen; Zhiqiang Li; Runhui Wu

Heliyon (Mar 2023)

Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China

Qian Xu,
Chunli Wang,
Wei Cheng,
Yingzi Zhen,
Yaguang Ding,
Guoqing Liu,
Wanru Yao,
Zhenping Chen,
Zhiqiang Li,
Runhui Wu

Affiliations

Qian Xu: Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China; Department of Hematology & Oncology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 611731, China
Chunli Wang: Nursing Department, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, China
Wei Cheng: Department of Cardiovascular Surgery II, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, China
Yingzi Zhen: Nursing Department, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, China
Yaguang Ding: Nursing Department, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, China
Guoqing Liu: Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China
Wanru Yao: Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China
Zhenping Chen: Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China
Zhiqiang Li: Department of Cardiovascular Surgery II, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, China
Runhui Wu: Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China; Corresponding author. 56 Nanlishi Rd, Beijing 100045, China.

Journal volume & issue: Vol. 9, no. 3
p. e13666

Abstract

Read online

Objectives: To report the perioperative management experience of central venous access devices (CVAD) in Chinese children with severe hemophilia A (SHA) in China. Methods: This retrospective study included SHA children who underwent Port-A-Cath or peripherally inserted central catheter (PICC) implantation between 2020/01 and 2021/07. Collected data included baseline characteristics, factor replacement regimen and CVAD-related complications. Results: Nine patients had nine ports placed, and eight patients underwent 10 PICCs placement. Patients without or with low-titer inhibitor (10 BU) received PICC. The median recombinant factor VIIa (rFVIIa) dose was 87.47 μg/kg before and for 5–7 doses after implantation over 2–3 days. The median PICC duration was 226.5 days, with infection incidence of 0.12 per 1000 catheter-days. Conclusions: CVADs can be safely implanted in China. PICC implantation is a practical and safe option for SHA children with high-titer inhibitors.

Published in Heliyon

ISSN: 2405-8440 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Science: Science (General); Social Sciences: Social sciences (General)
Website: https://www.cell.com/heliyon/home

About the journal

Abstract

Keywords